Program 10 Cancer Care Delivery Research

癌症护理交付研究计划 项目总结/摘要 癌症护理提供研究（CCDR）计划的使命是促进和开展研究， 确保为所有类型的癌症患者提供高质量、以患者为中心的护理。进展 癌症的诊断、筛查、预防和治疗通常是在定义和 研究对象相对较少。CCDR计划的成员衡量 当所报告的进展扩大到整个人口时，干预措施是有效的。该方案发展， 完善、测试和实施战略，以最大限度地发挥发现的影响。特别强调的一点 是研究发现的益处扩展到少数种族和民族患者的程度 社会背景和社会经济弱势群体。 该方案有66名成员（56名小学生和10名中学生），代表所有7个区/高等教育委员会机构， 12个学术部门。2019年，该计划的同行评审拨款为510万美元， NCI的直接费用和其他赞助商的770万美元。在本财政期间，主要 CCDR成员发表了1，336篇癌症相关论文。其中，25%是机构间的，23%是 39%是两个或两个以上DF/HCC成员之间的计划内合作。 CCDR强调改善癌症护理的经验，效率和公平性，确保创新 在癌症治疗和护理中，在整个人口和护理环境中充分发挥其潜力。满足 计划使命，CCDR成员建立了成功的合作，开发了新的研究方法， 构建数据源，并培训下一代临床研究人员。我们的具体目标 下一个CCSG资助期的任务是：1）评估新的和现有的 治疗癌症的干预措施，重点是精确医学，方法是（a）设计临床信息学 改善癌症护理提供的战略和（B）提高提供精确医疗的能力; 2） 评估以患者为中心的癌症护理结果，包括健康相关的生活质量和症状负担 通过开发评估患者体验的工具; 3）评估医疗保健改革的影响，包括 癌症筛查、诊断、治疗的替代交付、覆盖和报销系统， 结果;和4）制定和测试策略，以改善姑息治疗和临终关怀（EOL）的经验， 晚期癌症患者及其家属。

Cancer Care Delivery Research Program Project Summary / Abstract The mission of the Cancer Care Delivery Research (CCDR) Program is to facilitate and conduct research that ensures the delivery of high-quality, patient-centered care to individuals with all types of cancer. Advances in cancer diagnosis, screening, prevention, and treatment are usually tested and reported in defined and relatively small groups of research subjects. Members of the CCDR Program measure the extent to which interventions are effective when the reported advances are scaled population-wide. The Program develops, refines, tests, and implements strategies to maximize the impact of discoveries. A particular point of emphasis is the degree to which the benefits of research discoveries extend to patients from racial and ethnic minority backgrounds and to those who are socioeconomically disadvantaged. The Program has 66 members (56 primary and 10 secondary), representing all seven DF/HCC institutions and 12 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.1 million in direct costs from the NCI and $7.7 million from other sponsors. During the current funding period, primary CCDR members published 1,336 cancer relevant papers. Of these, 25% were inter-institutional, 23% were intra-programmatic, and 39% were inter-programmatic collaborations between two or more DF/HCC members. CCDR’s emphasis on improving the experience, efficiency, and equity of cancer care ensures that innovations in cancer treatment and care realize their full potential throughout populations and care settings. To meet the Program mission, CCDR members have built successful collaborations, developed new research methods, constructed data sources, and trained the next generation of clinical investigators. Our Specific Aims for the next CCSG funding period are to: 1) Assess the quality, effectiveness, and value of new and established interventions to treat cancer, with an emphasis on precision medicine by (a) designing clinical informatics strategies to improve cancer care delivery and (b) promoting capacity for delivering precision medicine; 2) Evaluate patient-centered outcomes of cancer care, including health-related quality of life and symptom burden by developing tools to assess the patient experience; 3) Assess the impact of healthcare reform, including alternative delivery, coverage, and reimbursement systems on cancer screening, diagnosis, treatment, and outcomes; and 4) Develop and test strategies to improve palliative and end of life care (EOL) experiences for advanced cancer patients and their families.